Radiopharm's Brain Cancer Imaging Agent Shows 92% Success in Phase 2 Trial
Radiopharm Theranostics (RADX) reports promising interim results for RAD 101, a novel brain metastases imaging agent, with 92% accuracy matching MRI scans in clinical trial.
/ 1 item
#RADX↓